Viewing nowCombinationJanuglume XR Tablet 100/1000 Milligrams
Sitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharm. Co., Ltd.

MFDS item code 202300595 · Approved 2023.02.17 · Insurance code 651205980
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication assists patients with type 2 diabetes in managing their blood sugar more effectively by using sitagliptin and metformin in conjunction with diet and exercise therapy. It is used to help improve blood sugar control to aid in diabetes management.
In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and should not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients. If a patient repeatedly reports finding this drug in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving treatment with metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving treatment with metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their existing doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily, based on their existing metformin dose. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used for the treatment of diabetes and helps in blood sugar control. However, there are some precautions to follow when taking this medication. First, allergic reactions may occur to the ingredients contained in this medication, so if symptoms of hypersensitivity appear, discontinue use immediately and consult a physician. Second, serious pancreatic inflammation known as acute pancreatitis may occur, so if symptoms such as abdominal pain, vomiting, or loss of appetite develop, immediately inform healthcare personnel. Third, it may be dangerous to take this medication if kidney function is impaired, so regular kidney function tests should be conducted, and if any abnormalities arise, consult a physician. Fourth, this medication can cause lactic acidosis, a rare but fatal metabolic complication, so if symptoms such as difficulty breathing, muscle pain, or fatigue occur, seek medical attention immediately. Fifth, there is a risk of hypoglycemia, so care should be taken when skipping meals or engaging in vigorous exercise, and if symptoms of hypoglycemia appear, sugar should be consumed immediately. Sixth, alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid alcohol while taking this medication. Seventh, before undergoing surgery or imaging tests with contrast agents, this medication should be temporarily discontinued, and it should be resumed only after verifying that kidney function is normal post-surgery. Eighth, it is safe for pregnant or breastfeeding women to avoid taking this medication. Ninth, elderly patients may easily experience decreased kidney function, so dose adjustment and regular kidney function testing are necessary. Finally, it is important to have regular blood tests and kidney function tests to monitor for abnormalities while taking this medication. This medication should be taken strictly according to a physician's prescription and instructions, and if any abnormal symptoms occur, consult healthcare personnel immediately.
anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, arthritis with severe and disabling symptoms, vesiculobullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, constipation, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, keeping it at room temperature between 1 and 30 degrees Celsius will help maintain the medication's effectiveness.
Light blue, bidirectional convex oval extended-release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharm. Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.